Novo Nordisk A/S
Business Model Analysis
How Novo Nordisk Makes Money
Annual Revenue: ~$47B
- How does Novo Nordisk make money?
- Novo Nordisk makes money from GLP-1 Diabetes Medicines, Obesity Care, Insulin And Diabetes Care and Rare Disease.
Novo Nordisk generates revenue primarily through Pharmaceuticals, with roughly ~$47B in annual revenue.
Core Growth Engine: Under CEO Mike Doustdar the strategy is to cut costs (about 9,000 roles targeted in 2025, with reported headcount down further since), push volume through cheaper self-pay and oral options such as the Wegovy pill, roll o...
Revenue Model & Pricing
Novo Nordisk sells prescription medicines through two segments. Diabetes and Obesity care is the bulk of sales: GLP-1 drugs (Ozempic, Rybelsus, Wegovy injection, the Wegovy pill launched in the US in January 2026 and Wegovy HD 7.2 mg), plus insulins such as Tresiba and NovoRapid. Rare disease covers haemophilia, growth hormone and other endocrine products. In the US, revenue depends on list prices, rebates to pharmacy benefit managers and government programmes such as 340B and Medicare, and increasingly on self-pay channels where patients buy Wegovy directly at lower prices. The US is the largest market; International Operations covers the rest of the world.
Core Revenue Streams
GLP-1 Diabetes Medicines
MajorOzempic, Rybelsus, and related diabetes products sold globally.
Obesity Care
Major growthWegovy and related obesity-care products sold through prescription channels.
Insulin And Diabetes Care
MaterialInsulin and other diabetes medicines across developed and emerging markets.
Rare Disease
ComplementaryHemophilia, growth hormone, and rare endocrine therapies.
Pipeline And Lifecycle Expansion
FutureNew indications, formulations, and next-generation metabolic medicines.
Growth Strategy
Under CEO Mike Doustdar the strategy is to cut costs (about 9,000 roles targeted in 2025, with reported headcount down further since), push volume through cheaper self-pay and oral options such as the Wegovy pill, roll out Wegovy 7.2 mg internationally, and rebuild the pipeline through deals such as the Akero Therapeutics acquisition for MASH and in-licensing agreements.
How Novo Nordisk Makes Money: FAQ
How does Novo Nordisk generate revenue across its global business divisions?
Novo Nordisk reported FY2025 net sales of ~$47 billion (DKK 309.1 billion) across two segments: Diabetes and Obesity care, which is the large majority of sales and includes Ozempic, Wegovy, Rybelsus and insulins, and Rare disease, which covers haemophilia and growth hormone products.
How important are GLP-1 drugs to Novo Nordisk?
GLP-1 medicines (Ozempic, Rybelsus, Wegovy and the Wegovy pill) generate most of Novo Nordisk's sales and growth. Its Q2 2026 outlook raise was driven by higher expectations for GLP-1 sales.
What are the geographic market sales proportions for Novo Nordisk?
The US is Novo Nordisk's largest market. International Operations covers Europe, China, Japan and emerging markets, where Wegovy and the Wegovy pill are being rolled out.
How does the commercial distribution of Ozempic and Wegovy operate?
Ozempic and Wegovy are prescribed by physicians and distributed through pharmaceutical wholesalers (McKesson, AmerisourceBergen/Cencora, Cardinal Health) to retail pharmacies and healthcare systems, packaged in proprietary pre-filled multidose FlexTouch or single-dose auto-injector pens.
What is the landmark $16.5 billion Catalent acquisition by Novo Holdings to expand fill-finish capacity?
In February 2024, parent company Novo Holdings agreed to acquire contract manufacturer Catalent for $16.5 billion, with Novo Nordisk subsequently purchasing three crucial Catalent sterile fill-finish drug product manufacturing facilities in Anagni (Italy), Bloomington (Indiana), and Brussels (Belgium) for $11.0 billion to resolve global Wegovy supply bottlenecks.
What is Rybelsus and how does it pioneer oral GLP-1 delivery?
Rybelsus is the world's first and only oral GLP-1 tablet for Type 2 diabetes. Novo Nordisk co-formulated semaglutide with an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), allowing delicate peptide molecules to withstand stomach acid and be absorbed directly through the gastric mucosa.
How does Novo Nordisk structure pricing and pharmacy benefit manager (PBM) rebates in the United States?
In the US, Novo Nordisk negotiates formulary placement with major Pharmacy Benefit Managers (CVS Caremark, Express Scripts, OptumRx), offering substantial gross-to-net rebates and commercial copay assistance cards to ensure broad commercial insurance coverage.
How does Novo Nordisk expand GLP-1 indications into cardiovascular and kidney disease?
In the landmark SELECT cardiovascular trial (17,604 non-diabetic patients), Wegovy demonstrated a 20% reduction in major adverse cardiovascular events (stroke, heart attack, cardiovascular death); in the FLOW trial, Ozempic demonstrated a 24% reduction in kidney disease progression in diabetic patients, unlocking multi-billion-dollar insurance coverage expansions.
Related Companies
Compare Novo Nordisk A/S With Competitors
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Eli Lilly and Company
Novartis AG
Bausch Health Companies Inc.
Pfizer
Johnson And Johnson
Gsk
Explore Novo Nordisk
Core profile pages, founders and related research hubs for this company.